Related Experiment Video
Updated: Aug 23, 2025
Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
Published on: April 22, 2019
HISMD: A Novel Immune Subtyping System for HNSCC
1State Key Laboratory of Oral Diseases, National Clinical Research Center for Oral Diseases, Research Unit of Oral Carcinogenesis and Management, Chinese Academy of Medical Sciences, West China Hospital of Stomatology, Sichuan University, Chengdu, China.
This study identifies three distinct immune subtypes in head and neck squamous cell carcinoma (HNSCC) using multi-omics data, revealing differences in prognosis and chemotherapy response. A novel deep learning system, HISMD, accurately predicts these subtypes from whole slide images.
Area of Science:
- Oncology
- Immunology
- Genomics
Background:
- Immune heterogeneity in head and neck squamous cell carcinoma (HNSCC) influences disease progression and treatment response.
- Existing immune subtyping methods often rely on single data types and lack comprehensive profiling.
Purpose of the Study:
- To identify comprehensive immune subtypes in HNSCC using multi-omics data.
- To develop and validate a novel deep learning-based prediction system for clinical application.
Main Methods:
- Multi-omics clustering (gene expression, somatic mutations) of 499 HNSCC patients from TCGA.
- Bioinformatic analysis to characterize immune features and biological differences.
- Development and validation of a deep learning model (HISMD) using whole slide images.
Main Results:
- Three immune subtypes were identified: adaptive immune activation (T cell-rich), innate immune activation (macrophage-rich), and immune desert.
- Adaptive and innate immune activation subtypes showed better survival and similar chemotherapy response compared to the immune desert subtype, which may be chemoresistant.
- The HISMD system demonstrated high accuracy, interpretability, and predictive stability in an independent cohort.
Conclusions:
- This study reveals significant immune heterogeneity in HNSCC.
- A novel, accurate, and interpretable immune subtyping prediction system (HISMD) was developed for HNSCC.
- Further validation and utility studies are needed for clinical implementation.
